Vinorelbine: A review of its use in elderly patients with advanced non-small cell lung cancer

Drugs and Aging

Volumn 19, Issue 9, 2002, Pages 695-721

  Curran, Monique P ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; VINBLASTINE; VINCRISTINE; VINDESINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ELDERLY CARE; ERYTHEMA; FATIGUE; FEVER; FUNCTIONAL ASSESSMENT; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HYPERTHERMIA; HYPESTHESIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHLEBITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REFLEX DISORDER; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; STOMATITIS; SURVIVAL RATE; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

EID: 0036033973     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219090-00006     Document Type: Review

References (116)

1. Parkin DM. Global cancer statistics in the year 2000., Lancet Oncol 200l Sep; 2 (9): 533-43
2. Sweeney CJ, Sandler AB. Treatment of advanced (stages III and IV) non-small-cell lung cancer. Curr Probl Cancer 1998 Mar-1998 30; 22 (2): 85-132
3. National Cancer Institute. SEER Cancer Statistics Review 1973-1999 [online]. Available from URL: http://www.cancer.gov [Accessed 2002 Aug 20]
4. Gridelli C, Maione P, Barletta E. Individualized chemotherapy for elderly patients with nonsmall cell lung cancer. Curr Opin Oncol 2002 Mar; 14 (2): 199-203
5. Gridelli C. Chemotherapy of advanced non small cell lung cancer in the elderly: An update. Crit Rev Oncol Hematol 2000 Sep; 35 (3): 219-25
6. Manegold C. Treatment of elderly patients with non small-cell lung cancer. Oncology (Huntingt) 2001 Mar; 15 (3 Suppl. 6): 46-51
7. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999 Dec 30; 341 (27): 2061-7
8. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994 Oct 1; 74 (7 Suppl.): 2208-14
9. Yancik R. Cancer burden in the aged: an epidermologic and demographic overview. Cancer 1997 Oct 1; 80 (7): 1273-83
10. National Cancer Institute. Non-small Cell Lung Cancer (PDQ): Treatment (Health Professional Version) [Online]. Available from URL: http://www.cancer.gov [Accessed 2002 Jul 20]
11. The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol) 1999; 11 (1): S1-S53
12. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997 Aug; 15: 2996-3018
13. Murren JR. Rationale for non-platinum chemotherapy in advanced NSCLC. Oncology (Huntingt) 2001 Jul; 15 (7 Suppl. 8): 29-34
14. Goa KL, Faulds D. Vinorelbine: A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 1994; 5 (3): 200-34
15. Coukell AJ, Noble S, Faulds D. Vinorelbine in advanced nonsmall cell lung cancer: A pharmacoeconomic review. Pharmacoeconomics 1999; 15 (4): 405-17
16. Gridelli C, De Vivo R. Vinorelbine in the treatment of non-small cell lung cancer. Curr Med Chem 2002 Apr; 9 (8): 879-91
17. Johnson SA, Harper P, Hortobagyi GN, et al. Vinorelbine: An overview. Cancer Treat Rev 1996 Mar; 22: 127-42
18. Aapro MS, Harper P, Johnson SA, et al. Developments in cytotoxic chemotherapy: Advances in treatment utilising vinorelbine. Crit Rev Oncol Hematol 2001 Dec; 40 (3): 251-63
19. Crawford J. Vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 1996 Apr; 23 Suppl. 5: 2-7
20. Gregory RK, Smith IE. Vinorelbine - A clinical review. Br J Cancer 2000; 82 (12): 1907-13
21. Ngan VK, Bellman K, Hill BT, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001 Jul; 60 (1): 225-32
22. Ngan VK, Bellman K, Panda D, et al. Novel actions of the antitumour drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000; 60: 5045-51
23. Kruczynaski A, Barret J-M, Etiévant C, et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vincaalkaloid. Biochem Pharmacol 1998; 55: 635-48
24. Binet S, Chaineau E, Fellous A, et al. Immunofluorescence study of the action of Navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990; 46 (2): 262-6
25. Fan M, Goodwin M, Vu T, et al. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 2000 Sep 29; 275 (39): 29980-5
26. Wang LG, Liu XM, Kreis W, et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999; 44 (5): 355-61
27. Kruczynski A, Etiévant C, Perrin D, et al. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 2002; 86: 143-50
28. Cros S, Wright M, Morimoto M, et al. Experimental antitumor activity of Navelbine. Semin Oncol 1989 Apr; 16 (2 Suppl. 4): 15-20
29. Gomi K, Ohno H, Nomura K, et al. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Jpn J Cancer Res 1992 May; 83 (5): 532-9
30. Photiou A, Sheikh MN, Bafaloukos D, et al. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol 1992; 118 (4): 249-54
31. Barret J-M, Etiévant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 2000; 45 (6): 471-6
32. Mogi H, Hasegawa Y, Watanabe A, et al. Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro. Cancer Chemother Pharmacol 1997 Jan; 39: 199-204
33. Ashizawa T, Miyoshi K, Asada M, et al. Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog (in Japanese). Jpn J Cancer Chemother 1993; 20 (1): 59-66
34. Ashizawa T, Asada M, Kobayashi E, et al. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice. Anticancer Drugs 1993 Oct; 4 (5): 577-83
35. Otter GM, Sirotnak FM. Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine. Cancer Chemother Pharmacol 1994; 33 (4): 286-90
36. Herbst RS, Lynch C, Vasconcelles M, et al. Gemcitabine and vinorelbine in patients with advanced lung cancer: Preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 2001 Aug; 48 (2): 151-9
37. Adams DJ, Knick VC. P-glycoprotein mediated resistance to I 5'-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 1995; 13 (1): 13-21
38. Etievant C, Barret J-M, Kruczynski A, et al. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998; 16 (1): 3-17
39. Etiévant C, Kruczynski A, Barret J-M, et al. Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol 2001 Jul; 48 (1): 62-70
40. Debal V, Allam N, Morjani H, et al. Characterisation of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids. Br J Cancer 1994 Dec; 70 (6): 1118-25
41. l. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996 Sep; 31: 184-97
42. Rahmani R, Bruno R, Iliadis A, et al. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). Cancer Res 1987 Nov 1; 47 (21): 5796-9
43. Rahmani R, Guéritte F, Martin M, et al. Comparative pharmacokinetics of antitumor Vinca alkaloids: Intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. Cancer Chemother Pharmacol 1986; 16 (3): 223-8
44. Bore P, Rahmani R, van Cantfort J, et al. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol 1989; 23 (4): 247-51
45. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 1991 Apr 15; 51 (8): 2073-6
46. Marquet P, Lachatre G, Debord J, et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992; 42 (5): 545-7
47. Gauvin A, Pinguet F, Culine S, et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000 Jul; 6 (7): 2690-5
48. Sabot C, Marquet P, Debord J, et al. Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur J Clin Pharmacol 1998 Apr; 54: 171-5
49. Schilling T, Fiebig HH, Kerpel-Fronius S, et al. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs 1996; 14 (4): 371-8
50. Van Heugen JC, De Graeve J, Zorza G, et al. New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr A 2001 Aug 10; 926 (1): 11-20
51. Nguyen L, Tranchand B, Puozzo C, et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002 May; 53 (5): 459-68
52. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001 Nov; 12 (11): 1643-9
53. Levêque D, Quoix E, Dumont P, et al. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1993; 33 (2): 176-8
54. Adenis A, Bonneterre J, Marty M, et al. Pharmacokinetic evaluation of the oral form of Navelbine® all along its clinical development [abstract no. 628P]. Ann Oncol 2000; 11 Suppl. 4
55. Urien S, Brée F, Breillout F, et al. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol 1993; 32 (3): 231-4
56. Zorza G, Guyomard C, Joly B, et al. In vitro metabolism of vinorelbine in rat, dog and human [abstract no. 197]. Thirteenth International Symposium on Microsomes and Drug Oxidations; 2000 Jul; Stresa Lake, Maggiore, Italy
57. Grudé P, Ratanasavanh D, Riché D, et al. Characterization of human cytochromes P450 isoenzymes involved in vinorelbine metabolism [abstract no. 179]. Thirteenth International Symbosium on Microsomes and Drug Oxidations. 2000
58. Puozzo C, Zorza G, Guimbaud R, et al. Metabolism of vinorelbine in human: Clinical application [abstract no. 1781]. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research; 2000 Apr; San Francisco, CA41: 280
59. Soudon J, Zorza G, Van Heugen J, et al. Search for vinorelbine metabolite activity: An in vitro cytotoxicity study using human ovary and lung cancer cell lines [abstract no. 2909]. 92nd Annual Scientific Meeting of the American Association of Cancer Research; 2001 Mar; New Orleans, LA
60. Focan C, Kreutz F, Leroy G, et al. Pharmacokinetics and massbalance elimination of 3H-vinorelbine following IV and oral administration to patients [abstract no. 2064]. 92nd Annual Scientific Meeting of the American Association of Cancer Research; 2001 Mar; New Orleans, LA, 42: 383
61. Balducci L. Perspectives on quality of life of older patients with cancer. Drugs Aging 1994 Apr; 4 (4): 313-24
62. Lichtman SM, Skirvin JA. Pharmacology of antineoplastic agents in older cancer patients. Oncology (Huntingt) 2000 Dec; 14 (12): 1743-55; discussion 1755
63. Lichtman SM, Villani G. Chemotherapy in the elderly: Pharmacologic considerations. Cancer Control 2000; 7 (6): 548-56
64. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997 Feb; 33 (2): 301-3
65. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996 Jan; 59 (1): 32-40
66. Levêque D, Jehl F, Quoix E, et al. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 1992 Dec; 32 (12): 1096-8
67. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999 Jan 6; 91 (1): 66-72
68. Gridelli C. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly lung cancer vinorelbine Italian study. Oncologist 2001; 6 Suppl. 1: 4-7
69. Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced nonsmall-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001 Feb-2001 31; 31 (2-3): 277-84
70. Gridelli C, Perrone F, Cigolari S, et al. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: Gemcitabine + vinorelbine vs gemcitabine in elderly advanced NSCLC patients [abstract no. 1230]. Proceedings of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco, CA20: 308a
71. Langer CJ. Elderly patients with lung cancer: biases and evidence. Curr Treat Options Oncol 2002 Feb; 3 (1): 85-102
72. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001 Dec; 34 Suppl. 4: S65-9
73. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000 Jul; 18 (13): 2529-36
74. Buccheri G, Ferrigno D. Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: A phase II study. Cancer 2000 Jun 15: 88: 2677-85
75. Colleoni M, Gaion F, Nelli P, et al. Weekly vinorelbine in elderly patients with non-small-cell lung cancer. Tumori 1994 Dec 31; 80 (6): 448-52
76. Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 1997 Mar; 33 (3): 392-7
77. Tononi A, Panzini I, Oliverio G, et al. Vinorelbine chemotherapy in non small cell lung cancer: Experience in elderly patients. J Chemother 1997 Aug; 9 (4): 304-8
78. Veronesi A, Crivellari D, Magri MD, et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996 Sep; 32A (10): 1809-11
79. Beretta GD, Michetti G, Belometti MO, et al. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 2000 Sep; 83 (5): 573-6
80. Feliu J, Gómez LL, Madrofial C, et al. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer 1999 Oct 15; 86: 1463-9
81. Perrone F, Gridelli S, Cigolari S, et al. Baseline assessment of quality of life (QOL) is a strong prognostic factor for survival of elderly patients with advanced non-small lung cancer (NSCLC). A secondary analysis of the MILES study. [abstract no. 1346] Proceedings of the American Society of Clinical Oncology; 2002 May 18-21; Orlando, FL21: 337
82. Baron FJ, Vázquez S, Fívida JL, et al. Sequential gemcitabine and vinorelbine in elderly patients with advanced non-small cell lung cancer. Preliminary results of a Galician multicenter phase II trial. Ann Oncol 2000; 11 Suppl. 4: 114
83. Lilenbaum R. Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine. Oncologist 2001; 6 Suppl. 1: 16-9
84. Lorusso V, Carpagnano F, Frasci G, et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 2000 Jan; 18 (2): 405-11
85. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40 (5): 373-83
86. Depierre A, Chastang CI, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer; a randomized trial. Annuals of Oncology 1994; 5: 37-42
87. Le Chevalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 2: 360-7
88. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998 Jul; 16 (7): 2459-65
89. Imperatori L, Lippe P, Laicai G, et al. Weekly cisplatin (P) and vinorelbine (V) is active and maneageable in advanced nonsmall cell lung cancer (ANSCLC) or poor performance status (PS) patients (PTS) [abstract no. F32]. Annuals of Oncology 2001; 12 Suppl. 4: 68
90. Martins SJ, Pereira JR, Ikari FK, et al. Chemotherapy (CT) with cisplatin and vinorelbine for elderly non-small cell lung cancer (NSCLC) patients [abstract no. 1804]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 18: 468a
91. Kelly K, Giarritta S, Hayes S, et al. Should older patients receive combination therapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of southwest oncology trials 9509 and 9308 [abstract no. 1313]. 37th Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco, CA20: 329a
92. Colleoni M, Vicario G, Nelli P, et al. Carboplatin and vinorelbine in elderly patients with non-small cell lung cancer. Oncol Rep 1996; 3 (6): 1035-8
93. Santomaggio C, Tucci E, Rinaldini M, et al. Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: A multicenter phase II study. Am J Clin Oncol 1998 Feb; 21 (1): 67-71
94. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994 Oct; 21 (5 Suppl. 10): 42-6; discussion 46-7
95. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nuts Forum 1995 May; 22 (4): 707-10
96. Pierre Fabre Limited. Vinorelbine (Navelbine®) Package Insert. 2002
97. GlaxcoSmithKline. US Vinorelbine Prescribing Information. 2001
98. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 1997 Oct 1; 80 (7): 1317-22
99. Gridelli C, Maione G, Colantuoni G, et al. Chemotherapy of non-small cell smallcell lung cancer in elderly patients. Curr Med Chem 2002; 9: 1487-95
100. Brown JS, Eraut D, Trask C, et al. Age and the treatment of lung cancer. Thorax 1996 Jun; 51 (6): 564-8
101. Crino L, Novello S, Migliorino MR, et al. A phase II randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): Impact of PS=2 vs 0 or 1 and age≥70 years vs <70 years on chemotherapy outcome [abstract no. 1258]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18 to 21; Orlando, FL
102. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 2001 Feb 15; 19 (4): 1064-70
103. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995 Oct 7; 311 (7010): 899-909
104. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10; 346 (2): 92-8
105. Noble S, Goa KL. Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997 Sep; 54 (3): 447-72
106. Plosker GL, Hurst M. Paclitaxel: A pharmacoeconomic review of its use in non-small cell lung cancer. Pharmacoeconomics 2001; 19 (11): 1111-34
107. Spencer CM, Faulds D. Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994 Nov; 48 (5): 794-847
108. Eisenhauer EA, Vermorken JB. The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs 1998 Jan; 55 (1): 5-30
109. National Institute for Clinical Excellence. Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer [Online]. Available from URL: http://www.nice.org.uk [Accessed 2002 Jul 22]
110. Recchia F, Lococo A, Campisi C, et al. Carboplatin, ifosfamide, and vinorelbine in the treatment of advanced non-small-cell lung cancer: A phase II study. Am J Clin Oncol 1999 Feb; 22 (1): 57-61
111. Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study. Lung Cancer 2000 Feb; 27 (2): 75-80
112. Baldini E, Ardizzoni A, Prochilo T, et al. Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol 2002 May; 49 Suppl. 1: S25-8
113. Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Nat Cancer Inst 2002; 94 (4): 291-7
114. Vokes EE, Rosenberg R, Jahanzeb M, et al. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report. Semin Oncol 1994 Oct; 21 Suppl. 10: 35-41
115. Jassem J, Ramlau R, Karnicka-Mlodkowska H, et al. A multi-center randomized phase II study of oral vs intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001 Oct; 12 (10): 1375-81
116. Vokes EE, Rosenberg RK, Jahanzeb M, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small lung cancer. J Clin Oncol 1995 Mar; 13 (3): 637-44